Indoco Remedies Limited has informed the Exchange about Update on the Company's testing facility at Chhatrapati Sambaji Nagar (Aurangabad)

Regulatory Product ApprovalBusiness Updates View source PDF

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.3%1-day move

₹211.16

prior close

₹223.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.5-0.2-1.3-0.7+2.3+2.8+1.3+0.9+1.8-2.7+16.9+6.6+13.6+18.2

Up moveDown movePending

AI summary

Indoco Remedies received a Pre-Approval Inspection from the U.S. FDA at its testing facility in Chhatrapati Sambaji Nagar (Aurangabad) from April 8-10, 2026. The inspection concluded with zero Form 483 observations, which is the best possible outcome. A Form 483 is issued when FDA investigators find conditions that may violate the Food, Drug, and Cosmetic Act. Zero observations indicate the facility meets all regulatory standards and is ready for product approvals. This suggests the company may be seeking approval to manufacture or supply products to the U.S. market.

Likely market impact

This is a strong positive development for shareholders as a zero 483 outcome removes a key regulatory hurdle. It enhances the company's credibility with global regulators and may open doors to U.S. market opportunities, potentially boosting future revenue from exports.